Compare BMRA & ACON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BMRA | ACON |
|---|---|---|
| Founded | 1971 | 2008 |
| Country | United States | United States |
| Employees | N/A | 11 |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5M | 8.1M |
| IPO Year | 1995 | N/A |
| Metric | BMRA | ACON |
|---|---|---|
| Price | $1.93 | $2.94 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 12.4K | ★ 56.3K |
| Earning Date | 04-13-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,311,000.00 | N/A |
| Revenue This Year | N/A | $87.22 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.87 | $2.34 |
| 52 Week High | $4.60 | $12.03 |
| Indicator | BMRA | ACON |
|---|---|---|
| Relative Strength Index (RSI) | 32.27 | 34.78 |
| Support Level | N/A | $2.38 |
| Resistance Level | $2.23 | $3.55 |
| Average True Range (ATR) | 0.13 | 0.20 |
| MACD | -0.04 | -0.04 |
| Stochastic Oscillator | 5.99 | 5.46 |
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focus on the development, manufacture, marketing, and sale of diagnostic products. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.